UnknownPhase 1NCT05223686

To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hrain Biotechnology Co., Ltd.
Principal Investigator
Jianqing Mi, Doctor
Ruijin Hospital
Intervention
Human CD19-CD22 Targeted T Cells Injection(drug)
Enrollment
18 enrolled
Eligibility
18-70 years · All sexes
Timeline
20222025

Study locations (1)

Collaborators

Ruijin Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05223686 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials